The case for & against
Bull & Bear analysis
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) is a biopharmaceutical company specializing in the development of RNA-targeted therapeutics aimed at treating severe genetic diseases and other high-risk medical conditions. As a leader in this innovative space, Ionis has cultivated a sizeable pipeline with both wholly-owned and partnered products. With the recent FDA approval of ZANVASTRO™ (zilganersen) for Alexander Disease and promising therapies such as Tringolza and Donzera, Ionis is positioned to leverage its pioneering research while enhancing patient access to critical therapies, thereby driving significant growth in the rapidly advancing biotechnology landscape.
Bull says
- ↑ZANVASTRO FDA approval could drive >$100M peak sales.
- ↑Tringolza Q2 revenue surged 3× to $19M.
- ↑Donzera Q2 sales reached $26M, up 63% QoQ.
- ↑Q2 cash reserves at ~$2.1B support R&D and launches.
- ↑Analysts maintain “buy” ratings with 72% upside to $100 PT.
- ↑Strong institutional backing and liquidity underpin stock stability.
Bear says
- ↓Non-GAAP op losses of $425–475M challenge profitability targets.
- ↓Profitability risk elevated amid weak earnings conversion and growth factors.
- ↓Olazarsen approval delays or failure could dent revenue projections.
- ↓Competitive saturation in rare diseases may limit market share gains.
- ↓Payer coverage hurdles threaten Tringolza and Donzera uptake.
- ↓Negative profitability and growth factors could dampen investor sentiment.
Investment themes with IONS
Genetic and drug innovations driving medical breakthroughs
Earnings Call · Q2 2025 · Mgmt. Guidance
Transcript signals
Bull points
- Tringolza exceeded revenue expectations during its second quarter on the market, underscoring its strong therapeutic profile, our well-executed commercial strategy, as well as the significant unmet need Tringolza is addressing.
- The revenue and commercial performance of Tringolza to date, along with our confidence in Tringolza's continued commercial success, supports the increase in our financial guidance for 2025,
- Together, these programs, in addition to two goals in FCS and Don Dolores and HAE, represent major breakthroughs for patients and represent multibillion-dollar revenue potential for Ionis.